In recent years, the relevant departments have actively promoted centralized drug procurement, which has played a certain role in promoting the return of drug prices to a reasonable level, but there are also some outstanding problems. The first is the decoupling of quantity and price. In the current bidding procurement, generally only the price is used instead of the quantity, so it is difficult for enterprises to achieve a sharp drop in drug prices because there is no sales expectation. Second, the competition is not sufficient. The quality level of generic drugs is generally low, so it is difficult to compete fairly with the original drugs. The price of some original drugs has been significantly higher than that of neighboring countries and regions for a long time, and the "patent cliff" has not happened in China. The third is decentralized procurement. Low purchasing level and scattered power lead to insufficient bargaining power, and regional policy differences affect the formation of a unified market and weaken the market competition mechanism. Fourth, there is a lack of coordination in policies. Measures such as drug procurement, use, medical insurance payment, payment and settlement are not coordinated enough to play a synergistic role.